Currently, the expression level of PD-L1 measured by immunohistochemistry (IHC) in NSCLC tumor samples is the sole biomarker approved by regulatory agencies to guide the decision treatment [18]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.